| No. | Trials | Comparisons | Sample size | Protocol | Duration | Outcomes |
| 1 | KUANG Heng (2014) [10] | BBR/MET | 23/28 | BBR:300mg tid/ | 3 months | BMI, WHR, FSH, LH, LH/FSH, T, HOMA-IR, TC, TG, HDL-C, LDL-C | MET:500mg bid |
| 2 | AN Yuan et al. (2014) (2016)[11, 12] | BBR/MET/P | 44/41/43 | BBR: 500mg tid/ | 3 months | BMI, WHR, FSH, LH, T, HOMA-IR, FBG, FIN, TC, TG, HDL-C, LDL-C | MET: 500mg tid/ | P: 1 tablet tid |
| 3 | LI Xiaobin e-t al. (2017) [13] | BBR/MET | 26/29 | BBR:300mg tid/ | 3 months | BMI, HOMA-IR, FSH, LH, LH/FSH, T, FPG, FIN, TC, TG, HDL-C, LDL-C | MET:500mg bid |
| 4 | WANG Ling-xiao et al. (2011) [14] | MET+BBR/MET | 28/28 | MET:500mg tid +BBR:500mg tid /MET:500mg tid | 3 months | BMI, LH, FSH, LH/FSH, T, FBS, FIN, HOMA-IR |
| 5 | WANG Ping et al(2016) [15] | MET+BBR/MET | 42/42 | MET:500mg tid +BBR:500mg tid /MET:500mg tid | 3 months | BMI, WHR, FSH, LH, LH/FSH, HOMA-IR, T, |
| 6 | MA Yukun e-t al. (2011) [4] | CPA+BBR/CPA/CPA+BBR +MET/ CPA+MET | 31/28/33/30 | CPA:1 tablet qd+BBR:500mg bid/ CPA:1 tablet qd / | 3 months | BMI, WHR, FPG, FIN, HOMA-IR, TC, TG, HDL-C, LDL-C, FSH, T, LH | CPA:1 tablet qd +BBR:500mg bid+MET:500mg tid | CPA:1 tablet qd +MET:500mg tid |
| 7 | WEI Wei et al.(2012) [16] | CPA+BBR/ CPA+MET/CPA +P | 31/30/28 | CPA 1 tablet qd+BBR:500mg tid / | 3 months | BMI, WHR, FPG, FIN, HOMA-IR, TC, TG, HDL-C, LDL-C | CPA 1 tablet qd +MET:500mg tid / | CPA 1 tablet qd + P:1 tablet bid |
| 8 | ZHU Qiuyan et al. (2016) [17] | CPA+BBR/ | 25/25 | CPA 1 tablet qd +BBR:300mg tid / CPA 1 tablet qd + P: 1 tablet tid | 3 months | BMI, WHR, FPG, HOMA-IR, TC, TG FSH, LH, T | CPA +P |
| 9 | CHEN Xiao et al.(2016) [18] | CPA+BBR/ | 50/50 | CPA 1 tablet qd +BBR:500mg bid / CPA 1 tablet qd | 3 months | TC, TG, HDL-C, LDL-C, FPG, FIN | CPA |
|
|